中國生物製藥(01177.HK)就一款治療哮喘藥物達成全球合作協議

阿斯達克財經

2024/12/05

中國生物製藥(01177.HK) 公布，集團和博奧信生物技術(南京)就聯合開發的TSLP單克隆抗體「BSI-045B (TQC2731)」，與Aclaris Therapeutics, Inc. (ACRS.US) 達成全球合作協議。據介紹，「BSI-045B (TQC2731)」是一款靶向胸腺基質淋巴細胞生成素(TSLP)的人源化單克隆抗體，可以阻止TSLP靶向的免疫細胞釋放促炎細胞因子。目前...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2489011484"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2489011484\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2489011484?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220712104954076_s.jpg","is_english":false,"pubTime":"2024-12-05 16:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489011484","market":"hk","top_or_hot":-1,"title":"中國生物製藥(01177.HK)就一款治療哮喘藥物達成全球合作協議","media":"阿斯達克財經","content":"<div>\n<p>中國生物製藥(01177.HK) 公布，集團和博奧信生物技術(南京)就聯合開發的TSLP單克隆抗體「BSI-045B (TQC2731)」，與Aclaris Therapeutics, Inc. (ACRS.US)  達成全球合作協議。據介紹，「BSI-045B (TQC2731)」是一款靶向胸腺基質淋巴細胞生成素(TSLP)的人源化單克隆抗體，可以阻止TSLP靶向的免疫細胞釋放促炎細胞因子。目前...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1402118&catg=4&source=AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中國生物製藥(01177.HK)就一款治療哮喘藥物達成全球合作協議</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中國生物製藥(01177.HK)就一款治療哮喘藥物達成全球合作協議\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2024-12-05 16:31</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>中國生物製藥(01177.HK) 公布，集團和博奧信生物技術(南京)就聯合開發的TSLP單克隆抗體「BSI-045B (TQC2731)」，與Aclaris Therapeutics, Inc. (ACRS.US)  達成全球合作協議。據介紹，「BSI-045B (TQC2731)」是一款靶向胸腺基質淋巴細胞生成素(TSLP)的人源化單克隆抗體，可以阻止TSLP靶向的免疫細胞釋放促炎細胞因子。目前...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1402118&catg=4&source=AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1402118&catg=4&source=AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心資產","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1402118&catg=4&source=AAFN","article_id":"2489011484","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220712104954076_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1402118&catg=4&source=AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2489011484","pubTimestamp":1733387460,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"中國生物製藥公布，集團和博奧信生物技術(南京)就聯合開發的TSLP單克隆抗體「BSI-045B 」，與Aclaris Therapeutics, Inc. 達成全球合作協議。據介紹，「BSI-045B 」是一款靶向胸腺基質淋巴細胞生成素的人源化單克隆抗體，可以阻止TSLP靶向的免疫細胞釋放促炎細胞因子。另外，Aclaris Therapeutics亦與博奧信生物技術(南京)達成許可協議，獲得「BSI-045B 」和另一款臨牀前產品在全球開發、生產和商業化的獨家授權。中國生物製藥將獲得以上交易對價的一部分。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","01177":"中国生物制药","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","BK1515":"抗疫概念"},"translate_title":"China Biopharmaceuticals (01177. HK) reaches a global cooperation agreement on an asthma drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"中國生物製藥(01177.HK) 公布，集團和博奧信生物技術(南京)就聯合開發的TSLP單克隆抗體「BSI-045B (TQC2731)」，與Aclaris Therapeutics, Inc. (ACRS.US)  達成全球合作協議。據介紹，「BSI-045B (TQC2731)」是一款靶向胸腺基質淋巴細胞生成素(TSLP)的人源化單克隆抗體，可以阻止TSLP靶向的免疫細胞釋放促炎細胞因子。目前，「BSI-045B (TQC2731)」正在中國開展III期臨牀試驗，全球開展II期臨牀試驗，適應症包括哮喘、慢性鼻竇炎伴有鼻息肉、特應性皮炎。另外，Aclaris Therapeutics亦與博奧信生物技術(南京)達成許可協議，獲得「BSI-045B (TQC2731)」和另一款臨牀前產品在全球(除中國大陸、澳門、香港、台灣)開發、生產和商業化的獨家授權。據合作協議及許可協議條款，Aclaris Therapeutics同意支付總計超過4,000萬美元(下同)現金，作為首付款以及承擔部分開發成本和藥物產品材料費用；19.9%的股權(總價值近5,400萬元)；總計潛在超過9億元的研發及銷售里程碑付款；單位數比例的銷售分成。中國生物製藥將獲得以上交易對價的一部分。(js/u)(港股報價延遲最少十五分鐘。沽空資料截至 2024-12-05 16:25。) (美股為即時串流報價； OTC市場股票除外，資料延遲最少15分鐘。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}